Erosa250 mg

Erosa 250 mg is effective against a wide variety of bacterial infections, including:

Upper Respiratory Tract Infections

• Tonsillitis and peritonsillar abscess
• Pharyngitis and laryngitis
• Sinusitis
• Secondary bacterial infections following colds and influenza

Lower Respiratory Tract Infections

• Tracheitis
• Acute and chronic bronchitis
• Community-acquired pneumonia, including atypical pneumonia caused by Mycoplasma pneumoniae and Legionella pneumophila

Ear Infections

• Otitis media
• Otitis externa
• Mastoiditis

Eye Infections

• Blepharitis
• Established trachoma

Skin and Soft Tissue Infections

• Boils and carbuncles
• Impetigo
• Abscesses
• Pustular acne
• Paronychia
• Cellulitis and erysipelas

Gastrointestinal Infections

• Cholecystitis
• Staphylococcal enterocolitis

Prophylactic Use

• Pre- and post-operative infection prevention
• Prevention of infection following trauma or burns
• Prevention of recurrent rheumatic fever

Other Infections

• Osteomyelitis
• Diphtheria (as an adjunct to antitoxin)
• Scarlet fever
• Whooping cough (pertussis)
• Nongonococcal urethritis and chlamydial genital infections, including during pregnancy when tetracyclines are contraindicated

Always take Erosa 250 mg exactly as prescribed by a registered physician. Self-medication with antibiotics can lead to treatment failure and antibiotic resistance.

Erosa 250 mg belongs to the macrolide group of antibiotics and is derived from the bacterium Streptomyces erythreus. Depending on the formulation, it is supplied as Erosa 250 mg stearate, Erosa 250 mg ethylsuccinate, or Erosa 250 mg base, all of which deliver the same active antibacterial compound once absorbed.

It produces a bacteriostatic effect at usual doses (stopping bacterial growth) and can become bactericidal (killing bacteria) at higher concentrations, by specifically interfering with protein synthesis inside the bacterial cell. Erosa 250 mg is particularly useful for treating infections caused by penicillinase-producing staphylococci and is often prescribed as a penicillin alternative in patients with penicillin allergy.

Organisms Susceptible to Erosa 250 mg

• Gram-positive bacteria: Most cocci and bacilli, including many strains of Staphylococcus and Streptococcus
• Gram-negative bacteria: Neisseria catarrhalis, Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus influenzae, Bordetella pertussis
• Other organisms: Mycoplasma pneumoniae, Legionella pneumophila, Bacteroides fragilis, Bacteroides oralis, Bacteroides melaninogenicus, Fusobacterium species, Chlamydia trachomatis, and Treponema pallidum

Erosa 250 mg inhibits microsomal protein synthesis in susceptible bacteria by blocking the translocation step of protein assembly. It binds specifically to the 50S ribosomal subunit (or the 70S ribosome in susceptible organisms) without attaching to the human body's own 80S ribosomes, which is why it can disrupt bacterial growth while sparing human cells. This selective action makes Erosa 250 mg effective against many gram-positive bacteria, several gram-negative organisms, and atypical pathogens such as Mycoplasma and Chlamydia.

Pharmacokinetics

Erosa 250 mg inhibits the liver enzyme CYP3A4, which can raise the blood levels of several other medications. Inform your doctor about all medicines you are taking before starting Erosa 250 mg.

Theophylline

In patients receiving high doses of theophylline, concurrent use of Erosa 250 mg can raise serum theophylline levels and increase the risk of theophylline toxicity. The theophylline dose may need to be reduced under medical supervision.

Other Clinically Significant Interactions

• Statins (e.g., lovastatin, simvastatin): Increased risk of muscle toxicity, including rhabdomyolysis, due to elevated statin levels.
• Warfarin: May enhance the anticoagulant effect, increasing bleeding risk; closer INR monitoring is advised.
• Digoxin: Erosa 250 mg can increase digoxin blood levels in some patients, raising the risk of digoxin toxicity.
• Carbamazepine, cyclosporine, tacrolimus: Erosa 250 mg can raise blood levels of these drugs, requiring dose monitoring.
• Ergot alkaloids (ergotamine, dihydroergotamine): Risk of acute ergot toxicity (ergotism), including severe peripheral vasospasm; co-administration should generally be avoided.
• Cisapride, pimozide, astemizole, terfenadine: Co-administration is contraindicated due to a significantly increased risk of serious heart rhythm disturbances (QT prolongation).
• Triazolam and midazolam: Erosa 250 mg may decrease the clearance of these benzodiazepines, increasing their sedative effect.
• Sildenafil: Erosa 250 mg can increase sildenafil exposure; a lower sildenafil dose may be considered.
• Hormonal contraceptives: May theoretically reduce the effectiveness of oral contraceptives; an additional contraceptive method is often recommended during treatment.

Most people tolerate Erosa 250 mg well, but like all antibiotics, it can cause side effects in some patients.

Seek prompt medical attention if you experience difficulty breathing, swelling of the face or throat, severe or persistent diarrhea, yellowing of the skin or eyes, or an irregular heartbeat while taking Erosa 250 mg.

Clinical and laboratory studies have shown no evidence of teratogenicity (birth defects) or toxicity to the developing fetus in humans. However, caution should still be exercised when prescribing Erosa 250 mg to pregnant or breastfeeding women, since the drug crosses the placental barrier and is excreted in breast milk.

Erosa 250 mg is sometimes specifically prescribed during pregnancy for chlamydial genital infections when tetracycline-class antibiotics are contraindicated. As with any medication during pregnancy or while breastfeeding, use should only be under the guidance of a qualified physician, who will weigh the benefits against any potential risks.

• Erosa 250 mg should be used with care in patients with impaired liver (hepatic) function, since it is excreted principally through the bile. Liver function may need to be monitored during prolonged therapy.
• Use cautiously in patients with myasthenia gravis, as macrolide antibiotics can occasionally worsen neuromuscular symptoms.
• High-dose or prolonged use, particularly in patients with kidney or liver impairment, has been associated with reversible hearing loss; report any ringing in the ears or hearing changes to your doctor.
• Infants under 2 weeks of age treated with Erosa 250 mg have a recognized association with infantile hypertrophic pyloric stenosis (IHPS); parents should watch for vomiting or irritability with feeding and report it to a pediatrician promptly.
• Patients with a history of QT prolongation, uncorrected electrolyte imbalances (especially low potassium or magnesium), or significant heart disease should use Erosa 250 mg with caution due to the risk of arrhythmia.
• Long courses of antibiotic therapy may result in overgrowth of non-susceptible organisms, including fungal infections; report any new or unusual symptoms during treatment.

In case of suspected overdose, Erosa 250 mg should be discontinued immediately and the patient should seek emergency medical care. Management focuses on prompt elimination of any unabsorbed drug (such as gastric lavage where appropriate) along with other supportive and appropriate measures as determined by a physician. Erosa 250 mg is not effectively removed from the body by peritoneal dialysis or haemodialysis.

Store Erosa 250 mg below 25°C, away from direct light and moisture. Keep all medicines, including Erosa 250 mg, safely out of the sight and reach of children.

1. Shake the bottle well to loosen the dry powder before adding water.
2. Add 60 mL or 100 mL of boiled and cooled water to the bottle, depending on the pack size specified on the label.
3. For ease of mixing, add the water in two portions, shaking well after each addition until the powder is fully suspended.
4. Shake the suspension thoroughly before each use to ensure an even dose.
5. Keep the bottle tightly closed between uses.
6. Store the reconstituted suspension in a cool, dry place — preferably in a refrigerator — and discard any unused portion after 7 days.